Drug Trial Radar · NCT05399888
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
416
Actual
Start
Aug 24, 2022
Primary completion
Mar 11, 2026
Study completion Jun 6, 2028
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Jun 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about a study drug called diranersen (BIIB080). The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if diranersen can slow the worsening of AD more than placebo. It will focus on what dose of diranersen slows worsening of AD the most. To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB. * Clinicians use the CDR-SB to measure several categories of dementia symptoms. * The results for each category are added together for a total score. Lower scores are better. Researchers will also learn more about the safety of diranersen. The study will be split into 2 parts. The 1st part is the Placebo-Controlled Period. The 2nd part is the Long-Term Extension (LTE) Period. The 2nd part of the study will help researchers learn about the long-term safety of diranersen, and how it affects the participant's daily life, thinking, and memory abilities in the longer term. A description of how the study will be done is given below. * After screening, participants will first receive either a low dose or high dose of diranersen, or a placebo, as an injection into the fluid around the spinal cord (cerebrospinal fluid). A placebo looks like the study drug but contains no real medicine. * Participants will receive diranersen or placebo once every 12 weeks or 24 weeks. * After 76 weeks of treatment in the Placebo-Controlled Period, eligible participants will move onto the Extension Treatment period, which will last 96 weeks. * In the extension period, participants who received placebo will be switched to high dose diranersen every 12 or 24 weeks. * Participants may be in the study for up to 201 weeks, or about 4 years. This includes the screening and follow-up periods. * Participants can continue to take certain medications for AD. Participants must be on the same dose of medication for at least 8 weeks before the screening period. * After the screening period, most participants will visit the clinic every 6 weeks.
Conditions
- Mild Cognitive Impairment Due to Alzheimer's Disease
- Alzheimer's Disease Dementia
Interventions
DiranersenDrug
Administered as specified in the treatment arm.
Diranersen-matching placeboDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose response in Change From Baseline to Week 76 on the CDR-SBTime frame: Baseline to Week 76
Locations
138 sites in 17 countries. Site status is shown where the registry gives one.
Xenoscience Inc.
Phoenix, Arizona
HonorHealth Neurology
Scottsdale, Arizona
Banner Sun Health Research Institute
Sun City, Arizona
Center for Neurosciences
Tucson, Arizona
Mary S. Easton Center for Alzheimer's Disease Research, UCLA
Los Angeles, California
PNS Clinical Research, LLC dba
Orange, California
Stanford Hospital and Clinics
Palo Alto, California
Sutter Institute for Medical Research
Sacramento, California
University of California San Diego Medical Center
San Diego, California
University of California San Francisco (PARENT)
San Francisco, California
Rocky Mountain Movement Disorders Center, PC
Englewood, Colorado
Charter Research, LLC
Lady Lake, Florida
K2 Medical Research, LLC
Orlando, Florida
Advent Health
Orlando, Florida
Conquest Research
Winter Park, Florida
Charter Research, LLC
Winter Park, Florida
Hawaii Pacific Neuroscience
Honolulu, Hawaii
Brigham and Women's Hospital Department of Neurology
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Lahey Clinic Medical Center - Burlington
Burlington, Massachusetts
Boston Center for Memory
Newton, Massachusetts
Neurological Associates of Albany, PC
Albany, New York
Dent Neurologic Institute
Amherst, New York
New York University Medical Center PRIME
New York, New York
South Shore Neurologic Associates, P.C.
Patchogue, New York
SUNY Upstate Medical University
Syracuse, New York
Duke University
Durham, North Carolina
AMC Research, LLC
Matthews, North Carolina
NeuroScience Research Center, LLC.
Canton, Ohio
University of Cincinnati Physicians Group, LLC
Cincinnati, Ohio
Butler Hospital
Providence, Rhode Island
Neurology Clinic, PC
Cordova, Tennessee
Neurology Consultants of Dallas, PA
Dallas, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas
EvergreenHealth
Kirkland, Washington
Kingfisher Cooperative, LLC
Spokane, Washington
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Southern Neurology
Kogarah, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.